Factors Associated With Mortality, Morbidity and Prognosis in Dementia Patients

Dementia; It is a chronic syndrome characterized by a general and progressive deterioration in cognition, including memory, orientation, language, and comprehension. The prognosis of this progressive and neurodegenerative disease after diagnosis may differ between individuals. In its broadest sense, the prognosis after a diagnosis of dementia; can be defined by shortening of life span, high level of cognitive and functional loss, decrease in quality of life and increased need for care. However, the prognosis of different types of dementia is highly variable. Because it is the most common type of dementia, studies are usually on Alzheimer's disease. It constitutes 50-75% of total dementia cases. Vascular dementia is the second most common cause of dementia and accounts for approximately 15% of dementia cases. Dementia with Lewy bodies constitutes 10-20% of the total dementia patients and ranks second among degenerative dementia types. Frontotemporal dementia, which mimics psychiatric disorders and has prominent behavioural problems, and Parkinson's disease-associated dementia, which is characterized by cognitive impairment that can be added to the existing picture in Parkinson's patients, are also counted among other types of dementia. Prognosis-related data on dementia types other than Alzheimer's disease are limited in the literature. Determining the prognosis is important to support patients, anticipate long-term health problems, plan physician and healthcare provision, and support patients with dementia.In view of the lack of sufficient data on dementia types other than Alzheimer's disease, it is aimed to contribute to the literature on this subject and to determine the factors that may affect prognosis, morbidity and mortality in patients belonging to all dementia types.

Study Overview

• Status: Completed
• Conditions: Dementia; Dementia, Vascular; Dementia, Mixed; Dementia With Lewy Bodies; Dementia of Alzheimer Type; Dementia Frontal
• Intervention / Treatment: Other: Observational

• Study Type: Observational
• Enrollment (Actual): 1000

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All patients diagnosed with any kind of dementia and being older than 60 years would be included in the study

Description

Inclusion Criteria:

Having applied to the Gulhane Training and Research Hospital Geriatrics Polyclinic Being diagnosed with Alzheimer or Lewy Body Dementia or Vascular Dementia or Fronto-Temporal Dementia or Parkinson Disease Dementia Being at the age of 60 years or older

Exclusion Criteria:

Being under the age of 60 Patients with insufficient recorded data and follow-up for the study Patients who either have diagnosis or follow-up in another center. Patients who have severe dementia that prevents applying for outpatient clinic

Study Plan

How is the study designed?

Number of groups / cohorts

5

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Dementia with Alzheimer; Patients previously diagnosed with Alzheimer disease would be included	Other: Observational; Patients data were collected throughout the following time
Dementia with Lewy Body Dementia; Patients previously diagnosed with Lewy Body Dementia would be included	Other: Observational; Patients data were collected throughout the following time
Dementia with Fronto-Temporal Dementia; Patients previously diagnosed with Fronto-Temporal Dementia would be included	Other: Observational; Patients data were collected throughout the following time
Dementia with Vascular Disease; Patients previously diagnosed with Dementia with Vascular Disease would be included	Other: Observational; Patients data were collected throughout the following time
Dementia with Parkinson Disease; Patients previously diagnosed with Dementia with Parkinson Disease would be included	Other: Observational; Patients data were collected throughout the following time

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mortality	The event of death occuring during the follow-up period	2 years
Mini-Mental State Examination	It was performed to assess mental status. It gives an overall opinion on cognitive domains and tests orientation, registration, attention and calculation, recall, and language. Total scores on Mini-Mental State Examination range from 0 to 30, higher scores show better cognitive performance.	2 years
Barthel Index	It was used for assessing physical functioning as a part of the routine geriatric evaluation.where the ten performance items used. Those items defined as feeding, bathing, grooming, dressing, continence of bowel and bladder, toilet use, transfers (bed to chair and back), mobility (on level surfaces), and climbing stairs. Each item is scored on this scale, and the sum is obtained by adding the score of each item (range, 0-100; higher scores show better performance)	2 years

Collaborators and Investigators

• Sponsor: Gulhane Training and Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2000
• Primary Completion (Actual): December 31, 2020
• Study Completion (Actual): December 31, 2020

Study Registration Dates

• First Submitted: September 8, 2021
• First Submitted That Met QC Criteria: September 12, 2021
• First Posted (Actual): September 22, 2021

Study Record Updates

• Last Update Posted (Actual): September 22, 2021
• Last Update Submitted That Met QC Criteria: September 12, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Neurocognitive Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Tauopathies; Intracranial Arterial Diseases; Intracranial Arteriosclerosis; Leukoencephalopathies; Dementia; Alzheimer Disease; Lewy Body Disease; Dementia, Vascular
• Other Study ID Numbers: 2021/290

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No